🔎 Trials Near Me

Hem › Akut myeloid leukemi › Kentucky › Louisville

Kliniska studier för Akut myeloid leukemi i Louisville, KY

12 studier för Akut myeloid leukemi söker deltagare vid platser i och runt Louisville (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.

Officiell studietext (engelska)

Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RekryterarFas 2
  • The James Graham Brown Cancer Center at University of Louisville, Louisville
  • UofL Health Medical Center Northeast, Louisville
Ålder 18 och äldre · Alla kön · Uppdaterad 5 okt. 2026 · NCT05564390

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

RekryterarFas 2
  • The James Graham Brown Cancer Center at University of Louisville, Louisville
  • UofL Health Medical Center Northeast, Louisville
Ålder 18 till 59 · Alla kön · Uppdaterad 28 sep. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

RekryterarFas 3
  • UofL Health Brown Cancer Center, Louisville
  • Norton Cancer Institute, Louisville
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT06852222

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RekryterarFas 2
  • The James Graham Brown Cancer Center at University of Louisville, Louisville
  • UofL Health Medical Center Northeast, Louisville
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RekryterarFas 2
  • The James Graham Brown Cancer Center at University of Louisville, Louisville
  • UofL Health Medical Center Northeast, Louisville
Ålder 18 till 59 · Alla kön · Uppdaterad 22 sep. 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RekryterarFas 2
  • The James Graham Brown Cancer Center at University of Louisville, Louisville
  • UofL Health Medical Center Northeast, Louisville
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RekryterarFas 3
  • Norton Children's Hospital, Louisville
6 Months – 21 Years · Alla kön · Uppdaterad 17 sep. 2026 · NCT04293562

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

RekryterarFas 3
  • Norton Children's Hospital, Louisville
Ålder 1 till 25 · Alla kön · Uppdaterad 4 sep. 2026 · NCT07022678

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

RekryterarFas 3
  • Norton Children's Hospital, Louisville
29 Days – 21 Years · Alla kön · Uppdaterad 24 aug. 2026 · NCT05183035

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RekryterarObservationsstudie
  • University of Louisville Hospital - James Brown Cancer Center, Louisville
Alla åldrar · Alla kön · Uppdaterad 6 juli 2026 · NCT01351545

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RekryterarFas 1
  • University of Kentucky Markey Cancer Center, Louisville
  • Norton Cancer Institute - St. Matthews, Louisville
Ålder 18 och äldre · Alla kön · Uppdaterad 13 mars 2026 · NCT05735184

Akut myeloid leukemi-studier i andra städer

Andra studier i Louisville

Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.